XKEM aktuel empfohlen unter:

Ja dann stelle doch mal bitte Informatiomen rein,das war doch dein Anliegen !
Also wider jemand der nur irgentwas sagen wollte.(Meckerfritze)

Hirschi  

ohne zu wissen, wo du deine Infos beziehst?

Hier: http://www.savannahtribune.com/index.php?page=article&id=232

hier:  http://www.tribune.com.ng/04082006/features.html

oder zB hier:  http://www.einnews.com/nigeria/newsfeed-nigeria-pharmaceuticals

Was soll ich zu dem aktuellen Stand der Dinge sagen? - Der Wert bewegt sich nicht.

lg
Meckerfritze
 

Erst einmal ein Dankeschön für die Infos(leider alle auf englisch)

Ich möchte mich  v o r  dem Kauf informieren  und nicht  o h n e  Infos kaufen.

Jetz habe ich ja die gewünschten Infos :-) auch wenn mein Fachenglisch nicht das Beste ist, werde ich es schon verstehen(dauert nur länger):-(

Viel Glück mit Xechem

Hirschi  

       Das mit dem Meckerfritze, bitte nicht sooo ernst nehmen :-)

Hirschi  

dann lese ich (denn hat man ja jeeeede Menge Zeit :) )  

Hirschi

 

...denn ich lese erst, kaufe dann, und bleib doch Monate drauf sitzen! ;-(

schönen abend noch
gianni  

Das ist doch ein Anfang. Eine News wird demnächst auch fällig!  

petruss

also bisher ist das nur die anpassung an den ami sk
von freitag! wollen wir mal hoffen das die heute auch wieder ein bischen ins grüne gehen...

allen investierten viel glück...  

Wenn das die Anpassung an den ami Kurs war, hätte er ins Minus gehen müssen.  

also am freitag haben die amis bei
0,0289 geschlossen das waren dann also so 0,0228 euro

da frankfurt am freitag mit 0,021 geschlossen hat war es meiner meinung
nach schon eine anpassung!

wenn du den knappen 0,001 euro meintest dann hattest du damit recht das es sich nicht um eine anpassung gehandelt hat...

aber ist ja eigentlich auch egal ist jetzt sowieso wieder geschichte!

schönen abend noch...
 

The Chairman of Xechem International, Inc. (OTC BB: XKEM), Dr. Ramesh C. Pandey, responded today to a number of questions posed by investors and others in the business community concerning the status of its operations in the aftermath of the approval of NICOSAN(TM), its sickle cell drug, by Nigerian regulators on July 3rd, 2006. Some of the questions posed to the company and answered by Dr. Pandey are the following:



Status of Production FacilityQ1: Xechem has reported that its Sickle Cell Drug, NICOSAN(TM), is
   being produced in limited quantities at its pilot scale facility
   in Abuja, and that construction has now begun on its full scale
   facility at the same location. When do you expect the full scale
   facility to be completed and at what cost?A1: We estimate that the construction of the new facility will be
   completed in approximately nine to twelve months, subject to
   timely receipt of the required funds, and the facility will be
   fully operational then. Our current estimate is that the total
   cost of the new facility, including the cost of the required
   machinery and equipment, will be approximately $12 to $15 million,
   of which over $5 million has already been invested by the Company.Expected Sources of FundingQ2: What are the sources of the expected funding to finance the
   capital expenditures?A2: In the past several weeks, we received a loan from NEXIM Bank of
   Nigeria for 150 million Naira (USD $1.2 million). The bulk of
   those proceeds have been earmarked for the initial phase of
   construction, and that work has recently begun. NEXIM has been an
   extremely supportive lender that likes very much what Xechem is
   doing in Nigeria and has expressed a strong interest in investing
   significantly more money into Xechem's operations there. In fact,
   advanced discussions are now underway with NEXIM officials
   concerning a substantial new loan, the proceeds of which would be
   used primarily for constructing the buildings for the new
   commercial scale facility. We are also continuing to aggressively
   pursue an approximately $8 to $9 million loan through the U.S.
   Export-Import Bank Loan Guarantee Program.Q3: Can you provide a report on the status of the Ex-Im loan and the
   likelihood that it will close in the near future?A3: As with any significant commercial loan to a company at our stage
   of development, issues arise during the course of negotiation and
   due diligence that can affect the timing of any proposed
   transaction. This was especially true prior to July 2006, when we
   received regulatory approval from Nigeria's National Agency for
   Food and Drug Administration and Control (NAFDAC). That approval
   added quite a bit of credibility to our efforts, particularly in
   procuring the required local Nigerian bank guarantee, and has
   seemed to accelerate the pace of negotiations with the various
   parties involved with the Ex-Im guaranteed loan. Although
   certainly there are no assurances as to when or if this loan will
   close, I believe we have satisfied all of the statutory and other
   requirements for the transaction and my sense is that this loan
   has an excellent chance of being approved in the near future.Q4: Do you believe the government of Nigeria may step up and agree to
   provide financial support to Xechem in one form or another?A4: In my judgment, the government of Nigeria has an incentive to
   offer financial support to Xechem for at least three important
   reasons. First, we have licensed our product from Nigeria's
   National Institute for Pharmaceutical Research and Development
   (NIPRD), which stands to benefit directly from our financial
   success through the gross royalty they will receive from the sale
   of our product. Second, there is no place in the world where
   NICOSAN(TM) is more desperately needed than Nigeria and I believe
   that the government has a strong incentive on humanitarian grounds
   to help insure that the drug reaches as many of its citizens as
   can be accomplished. And third, Nigeria is working very hard to
   improve its image internationally and to promote corporate
   investment, especially by American companies. The government of
   Nigeria knows that Xechem is being closely watched by investors
   and others in the business community who want to see if an
   American company like Xechem can be truly successful in Nigeria.
   For all of these reasons, I believe that the government of Nigeria
   would consider offering Xechem substantial financial support in
   one form or another under the right circumstances .Q5: Has Xechem already approached the Nigerian government about the
   possibility of providing Xechem some form of financial
   accommodation?A5: As with many aspects of the development of our business, until our
   drug was formally approved by the regulators in Nigeria, it was
   impossible to have meaningful dialogue concerning possible
   governmental support for Xechem in whatever form. Now that the
   drug has been approved, those doors have been opening, in some
   case widely, and that has been the case concerning possible
   governmental support. While I cannot speak to the details of those
   discussions or comment on the possible timing or likelihood of
   working directly with the government to support our operations
   financially, I can say that we are having high level conversations
   with government officials concerning a possible pre-purchase of
   large scale quantities of our product for distribution by the
   government in the country's national hospitals.
Current and Projected Sales ActivityQ6: Turning to the drug itself, have sales of the product begun and,
   if so, how is the drug being distributed?A6: We have begun sales of the product on a limited basis in Abuja.
   Because we are producing pilot scale quantities which are
   insufficient to meet the expected demand for the product, we have
   strictly limited distribution of the drug so that, at present, it
   can only be acquired at Xechem Nigeria's headquarters at Sheda
   Science and Technology Complex (SHESTCO), Abuja. Soon, we expect
   to open three to four satellite offices in Abuja. These measures
   will last until the full scale facility is completed when we will
   turn to more traditional avenues of marketing and distribution
   throughout Nigeria and beyond. Keep in mind that once on the
   medicine, a patient must continue taking it on a daily basis
   without interruption in order for the drug to be effective. One of
   our big concerns is making sure that once a patient begins taking
   the medicine, that person will have uninterrupted access to the
   drug going forward.Q7: How many patients do you expect to serve before the completion of
   the full-scale facility?A7: Based on the quantities of the finished product now on hand and
   our current small-scale production capability, we project that we
   will be able to meet the needs of approximately 20,000 patients
   per month on an annualized basis pending completion of the
   full-scale facility.Q8: What is the current price for the drug and what sales volume do
   you forecast for this initial period prior to full-scale
   production?A8: We are currently charging 3000 Naira (USD $23) per month for adult
   patients and 2400 Naira (USD $18.50) per month for children. If we
   meet our target of supplying 20,000 patients per month on average
   during the first year, this will result in annual sales of
   approximately $5 million during this period of limited production
   capability. That number could be significantly higher if, as we
   expect, we are successful in achieving some incremental increase
   in capacity between now and the time the full-scale facility is
   completed.Q9: Once the expanded production facility is completed, what do you
   feel is the market potential for this drug?A9: There are approximately 4 million people in Nigeria alone
   afflicted with Sickle Cell Disease, of whom we believe upwards of
   50% live in urban or quasi-urban areas where average income levels
   are believed to be sufficiently high to absorb the retail cost of
   the product. Realistically, we believe we should be able to
   penetrate more than half of that segment of the market over a five
   year period, which would result in estimated annual revenues to
   Xechem Nigeria of approximately $200 million at today's prices.
   And that is for Nigeria alone. Needless to say, down the road, we
   expect to generate additional revenues from sales of the product
   throughout Africa, not to mention India and the Middle East and,
   of course, Europe and the United States. Also, these figures do
   not take into account additional sales that may be possible to
   poorer segments of Nigerian society as part of a pre-purchase or
   other support program with the government of Nigeria.Q10: Can you speak to the substantial decline in the price of Xechem
   stock that has occurred since the launch?A10: There are many theories on that, and it's probably best for me
   not to address them directly. What I do feel comfortable in saying
   is that we have something very special going on in Nigeria right
   now and have unquestionably accomplished a great deal in getting
   to this point in spite of the many obstacles in our path. I am
   confident that as we secure one or more traditional bank type
   financings and move forward in the implementation of our business
   plan, things will change markedly for Xechem and its shareholders.
   My message to our shareholders is this: the patient investor will
   be rewarded as we progress toward full scale production of this
   historical drug.

NICOSAN(TM) is an anti-sickling drug developed by Nigerian scientists at the National Institute for Pharmaceutical Research and Development (NIPRD). In clinical studies conducted under NIPRD's auspices, the drug has shown to substantially reduce the degree of sickling of the red blood cells of those afflicted with the disease. While not a cure, the clinical trials have confirmed that the large majority of patients taking NICOSAN(TM) no longer experience sickle cell "crises" while on the medication, and even among those whose crises are not eliminated, the number and severity of the crises are substantially reduced.



About Xechem



Xechem International is a development stage biopharmaceutical company working on anticancer, antiviral (including AIDS), antifungal, antimalarial and antibacterial products from natural sources, including microbial and marine organisms. Its focus is on the development of phyto-pharmaceuticals (natural herbal drugs) and other proprietary technologies, including those used in the treatment of orphan diseases. Xechem's mission is to bring relief to the millions of people who suffer from these diseases. Its recent focus and resources have been directed primarily toward the development and launch of NICOSAN(TM) (to be marketed as HEMOXIN(TM) in the US and Europe). With the Nigerian regulatory approval now in hand, Xechem will now turn to the commercialization of the drug in Nigeria and the pursuit of US FDA and European regulatory approval. In addition to NICOSAN(TM), Xechem is also working on another sickle cell compound, 5-HMF, which it has licensed from Virginia Commonwealth University.



Forward Looking Statements



This press release contains certain forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities and Exchange Act of 1934, as amended, which are intended to be covered by safe harbors created hereby. Such forward-looking statements involve known and unknown risks and uncertainties.
 

10:26:05 Q 0.025 -   30,000
          §10:24:58 Q 0.025 -   5,000
          §10:24:56 Q 0.0249 -0.0001 148,574
          §10:24:24 Q 0.025 -   5,000
          §10:24:19 Q 0.0248 -0.0002 67,000
          §10:24:17 Q 0.0248 -0.0002 20,000
          §10:24:17 Q 0.025 -   20,000
          §10:24:04 Q 0.0249 -0.0001 65,000
          §10:24:04 Q 0.025 -   65,000
          §10:23:39 Q 0.0248 -0.0002 79,000


Kurs zieht an! In Amerika schon 500 Trades.
http://bigcharts.marketwatch.com/markets/...ge=118&screen=7&x=34&y=21  

in Deutschland einige Xechem Aktien obwohl die News noch nicht draussen waren. Ein Vorsprung von ca. +16% ! Das ist ja ein Zufall...  

heute ist XechemTIME:

       10:33:26 Q 0.0259 +0.0009 45,000
          §10:32:59 Q 0.025 -   20,000
          §10:32:45 Q 0.0259 +0.0009 5,000
          §10:32:24 Q 0.0259 +0.0009 5,000
          §10:32:04 Q 0.0259 +0.0009 5,000
          §10:31:59 Q 0.026 +0.001 5,000
          §10:31:49 Q 0.026 +0.001 4,000
          §10:31:49 Q 0.026 +0.001 115,000
          §10:31:49 Q 0.026 +0.001 235,000
          §10:31:19 Q 0.0259 +0.0009 250,000

Erfahrungsgemäß ist der Kurs in einigen Stunden bei +80%  

du bist ein sabbelkopf :-)  

                  Cumulative
                                         Six months Ended   Inception to
                                             June 30,         June 30,
                                        -----------------   ------------
                                          2006      2005        2006
                                        -------   -------   ------------
                                          (in thousands)
Revenue                                  $     2   $     3     $  2,123
Research and Development Expense         $   834   $   473     $ 15,486
General and Administrative Expenses      $ 2,831   $ 1,650     $ 27,083
Writedown of Inventory And Intangibles   $    --   $    --     $  1,861
Loss from Operations                     $(3,663)  $(2,120)    $(42,307)
Other Income (Expense)                   $  (859)  $(2,772)    $(36,131)
Net Loss before Income Taxes             $(4,522)  $(4,892)    $(78,438)
Income Tax Benefit                       $    --   $    --     $  2,636
Net Loss before Income Taxes             $(4,522)  $(4,892)    $(75,802)

http://biz.yahoo.com/e/060821/xkem.ob10qsb.html

lg
o  

zu 0,017 dabei!Kleine Erholung steht an!  

 

0,031 gefallen auf 0,0215 USD,ich denke rein techn. ist ein reversal bis 0,027 möglich.
Umsätze in den usa stark rückläufig,was bedeutet der Abverkauf hat stark nachgelassen,so das eine Wende rein techn. bevorsteht.
Auch darf man nicht vergessen wo sie vor 6 Wochen stand: 9 US cent!  

mit 0,016 unter dem Schlusskurs in den USA-0,0215 umgerechnet knapp 0,017
Also: noch Schnäppchenpreis!  

wenn die in den usa nur twas höher heute nachmittag rein kommen gibt es hier keine mehr
unter 0,02!  

gibt es denn news oder irgendetwas neues?  

höher als die letzten Tage! Auch gutes Zeichen.Hier denken einige ebenso wie ich.  

ich will ja meinen teil zum volumen beitragen.